PharmiWeb.com - Global Pharma News & Resources
08-Jan-2019

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

PR Newswire

SAN FRANCISCO, Jan. 8, 2019

SAN FRANCISCO, Jan. 8, 2019 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Amy Huang, General Manager, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:00 a.m. PST/12 noon EST, in San Francisco, CA.

About OBI Pharma, Inc.

OBI Pharma has a diverse portfolio of innovative cancer therapies at various stages of development. OBI is focused on the development of novel active and passive immune therapies including therapeutic vaccines, antibody drug conjugates, monoclonal antibodies, and a tumor-specific prodrug targeting the enzyme AKR1C3.

OBI Pharma is the only company with a mid-to-late-stage immuno-oncology pipeline targeting the Globo Series of glycosphingolipids Globo H, SSEA-3, and SSEA-4 and has the potential to combine Globo Series antibodies with antibodies against other targets such as PD-L1, VEGF, OX-40, and CD-40 to expand its portfolio of bispecifics.

OBI Pharma has initiated a global Phase 3 trial in Triple Negative Breast Cancer patients with Adagloxad Simolenin, a therapeutic vaccine targeting the antigen Globo H ceramide which is expressed on the surface of epithelial tumor cells. 

OBI Pharma has received orphan drug status for two products in Phase 1 development: OBI-888, a first-in-class monoclonal antibody targeting Globo H in patients with pancreatic cancer, and OBI-3424 a prodrug targeting tumors expressing the enzyme AKR1C3 in patients with acute lymphoblastic leukemia (ALL) and hepatocellular carcinoma (HCC). 

For more information, please visit www.obipharma.com

Forward-Looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

COMPANY CONTACT:
Kevin Poulos
Chief Commercial Officer
OBI Pharma USA, Inc.
Ph: 619-537-7698 Ext 102
kpoulos@obipharmausa.com

 

View original content:http://www.prnewswire.com/news-releases/obi-pharma-inc-to-present-at-the-jp-morgan-healthcare-conference-300774838.html

SOURCE OBI Pharma, Inc.

Editor Details

Last Updated: 08-Jan-2019